Trial Profile
Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Cytarabine; Mitoxantrone; Topotecan
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 07 Mar 2023 Status changed from recruiting to completed.
- 10 Jun 2015 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently.
- 17 Sep 2008 New trial record.